Bill Text: IL HB1443 | 2025-2026 | 104th General Assembly | Engrossed

---

Bill Title: Reinserts the provisions of the introduced bill with the following changes. Makes changes to defined terms. Replaces references to the Health Care Availability and Access Board, the Health Care Availability and Access Stakeholder Council, and the Health Care Availability and Access Board Fund to the Prescription Drug Affordability Board, the Prescription Drug Affordability Stakeholder Council, and the Prescription Drug Affordability Board Fund. Requires Prescription Drug Affordability Board membership to also include individuals with expertise in the practice of pharmacy. Includes reimbursements from health benefit plans in provisions concerning upper payment limits for payor reimbursements. Requires the Board to maintain financial records and accounts in accordance with generally accepted governmental accounting principles. Provides that the Board shall be deemed a public body for purposes of the Freedom of Information Act and the Open Meetings Act; all records of the Board, including meeting minutes, cost review records, and correspondence, shall be public records subject to disclosure in accordance with the Freedom of Information Act, except as otherwise provided by law; and meetings of the Board shall be open to the public in accordance with the Open Meetings Act. Requires the Board to establish an operational plan for distribution and access to a drug with an upper payment limit before the Board reviews specific drugs for affordability and establishes any upper payment limits. Provides that the Board shall prioritize establishing and implementing upper payment limits for the 10 prescription drug products with a Medicare Maximum Fair Price that went into effect in 2026 before proceeding with upper payment limits on other prescription drug products with a Medicare Maximum Fair Price or affordability reviews for any other prescription drug products. Adds more items to the list of information that may be included to conduct an affordability review. Provides that the Board may suspend an upper payment limit if it determines that there is a shortage of the drug in the State unless the Board determines that the shortage was caused by a manufacturer or its agent. Changes expertise requirements for membership of the Prescription Drug Affordability Stakeholder Council. Establishes specified exemptions for the Department of Healthcare and Family Services and other State departments in provisions concerning protections and other Board considerations. Provides that any upper payment limit established by the Board shall not apply to prescription drug products purchased by the Department of Healthcare and Family Services for the medical assistance program under Article V of the Illinois Public Aid Code or to a health care plan serving Medicaid populations that provides, arranges for, pays for, or reimburses the cost of any health care service for persons who are enrolled under the medical assistance program under Article V of the Illinois Public Aid Code unless, after consultation with and approval of the Director of Healthcare and Family Services, it is determined that the upper payment limit would reduce costs to the State. Provides that, if a prescription drug product subject to an upper payment limit established under the Act is intended to be made available for purchase by pharmacies, distributors, or wholesalers licensed in the State, it shall be available at a price that does not exceed the upper payment limit (rather than a wholesaler or distributor shall make any prescription drug product that is subject to an upper payment limit established under the Act available for purchase by pharmacies licensed in this State at a price that does not exceed the established upper payment limit), and, if a wholesaler or distributor acquires a prescription drug product subject to an upper payment limit at a price that exceeds the upper payment limit, the wholesaler or distributor is entitled to a chargeback or rebate equal to the difference between the price and the upper payment limit from the entity that sold the product to the wholesaler or distributor. Changes the required reporting date for the Board concerning the operation of the generic drug market in the United States to June 1, 2027 (rather than June 1, 2025). Requires the Board to notify the General Assembly if 5 years have passed without any litigation hindering Board operations. Provides that the Act is repealed 5 years after the effective date of the Act. Makes other changes. Effective 180 days after becoming law.

Sponsorship: Partisan Bill (Democrat 30)

Status: (Introduced - Dead) 2026-04-17 - House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee [HB1443 Detail]

Download: Illinois-2025-HB1443-Engrossed.html

---

HB1443 Engrossed LRB104 06394 BAB 16430 b
AN ACT concerning health.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 1. Short title. This Act may be cited as the
Prescription Drug Affordability Board Act.
Section 5. Definitions. In this Act:
"Biologic" means a drug that is produced or distributed in
accordance with a biologics license application approved under
42 U.S.C. 1395w-3a(c)(6).
"Biosimilar" means a drug that is produced or distributed
in accordance with a biologics license application approved
under 42 U.S.C. 262(k)(3).
"Board" means the Prescription Drug Affordability Board.
"Brand name drug" means a drug that is produced or
distributed in accordance with an original new drug
application approved under 21 U.S.C. 355(c). "Brand name drug"
does not include an authorized generic drug as defined by 42
CFR 447.502.
"Council" means the Prescription Drug Affordability
Stakeholder Council.
"Generic drug" means:
(1) a retail drug that is marketed or distributed in
accordance with an abbreviated new drug application,

HB1443 Engrossed - 2 - LRB104 06394 BAB 16430 b
approved under 21 U.S.C. 355(j);
(2) an authorized generic drug as defined by 42 CFR
447.502; or
(3) a drug that entered the market before 1962 that
was not originally marketed under a new drug application.
"Health benefit plan" has the meaning given to that term
in Section 513b1 of the Illinois Insurance Code.
"Manufacturer" means an entity that:
(1) owns the patent to a prescription drug product; or
(2) enters into a lease with another manufacturer to
market and distribute a prescription drug product under
the entity's own name;
(3) is the labeled entity of the generic product at
the point of manufacture; and
(4) sets or changes the wholesale acquisition cost of
the prescription drug product it manufactures or markets.
"Prescription drug product" means a brand name drug, a
generic drug, a biologic, or a biosimilar.
"Wholesale acquisition cost" has the meaning given to that
term in 42 U.S.C. 1395w-3a.
Section 10. Prescription Drug Affordability Board.
(a) There is established a Prescription Drug Affordability
Board. The purpose of the Board is to protect State residents,
State and local governments, commercial health plans, health
care providers, pharmacies licensed in the State, and other

HB1443 Engrossed - 3 - LRB104 06394 BAB 16430 b
stakeholders within the health care system from the high costs
of prescription drug products. The Board is a public body and
is an instrumentality of the State. The Board is an
independent unit of State government. The exercise by the
Board of its authority under this Act is an essential
function.
(b)(1) The 5 members of the Board and 3 alternate members
shall be appointed by the Governor with the advice and consent
of the Senate.
(2) The Board membership must include individuals with
demonstrated expertise in health care economics,
pharmaceutical markets, the practice of pharmacy, and clinical
medicine. A member or an alternate member may not be an
employee of, a Board member of, or a consultant to a
manufacturer or trade association for manufacturers.
(3) Any conflict of interest, including whether the
individual has an association, including a financial or
personal association, that has the potential to bias or has
the appearance of biasing an individual's decision in matters
related to the Board or the conduct of the Board's activities,
shall be considered and disclosed when appointing members and
alternate members to the Board.
(c) The term of a member or an alternate member is 5 years,
except that the terms of the initial members and alternate
members shall be staggered as required by the terms provided
for members in Section 55. Board members shall be appointed

HB1443 Engrossed - 4 - LRB104 06394 BAB 16430 b
within 90 days after the effective date of this Act. The Board
may begin its work regardless of a delay in appointments to the
Prescription Drug Affordability Stakeholder Council created
under Section 20.
(d) The Chair shall hire an executive director, general
counsel, and staff for the Board. Staff of the Board shall
receive a salary as provided in the budget of the Board. A
member of the Board: (i) may receive compensation as a member
of the Board; and (ii) is entitled to reimbursement for
expenses.
(e) A majority of the members of the Board shall
constitute a quorum for the purposes of conducting the
business of the Board.
(f) Subject to the requirements of this subsection, the
Board shall meet in open session at least 4 times per year to
review prescription drug product information. Information
concerning the location, date, and time of the meeting must be
made publicly available in accordance with the Open Meetings
Act. The Chair may cancel or postpone a meeting if there is no
business to conduct.
The Board shall perform the following actions in open
session: (i) deliberations on whether to subject a
prescription drug product to a cost review under subsection
(f) of Section 25; and (ii) any vote on whether to impose an
upper payment limit on purchases, payments, and payor
reimbursements, including reimbursements from health benefit

HB1443 Engrossed - 5 - LRB104 06394 BAB 16430 b
plans, of prescription drug products in the State. The Board
may otherwise meet in closed session to discuss proprietary
data and information.
The Board shall provide public notice of each Board
meeting at least 3 weeks in advance of the meeting. Materials
for each Board meeting shall be made available to the public at
least 3 weeks in advance of the meeting. The Board shall
provide an opportunity for public comment at each open meeting
of the Board. The Board shall provide the public with the
opportunity to provide written comments on pending decisions
of the Board. The Board may allow expert testimony at Board
meetings, including when the Board meets in closed session.
(f-5) The Board shall maintain financial records and
accounts in accordance with generally accepted governmental
accounting principles. The Board shall be deemed a public body
for purposes of the Freedom of Information Act and the Open
Meetings Act. All records of the Board, including meeting
minutes, cost review records, and correspondence, shall be
public records subject to disclosure in accordance with the
Freedom of Information Act, except as otherwise provided by
law. Meetings of the Board shall be open to the public in
accordance with the Open Meetings Act.
(g)(1) Members of the Board shall recuse themselves from
decisions related to a prescription drug product if the
member, or an immediate family member of the member, has
received or could receive any of the following:

HB1443 Engrossed - 6 - LRB104 06394 BAB 16430 b
(A) a direct financial benefit of any amount deriving
from the result or finding of a study or determination by
or for the Board; or
(B) a financial benefit from any person who owns,
manufactures, or provides prescription drug products,
services, or items to be studied by the Board that in the
aggregate exceeds $5,000 per year.
As used in this paragraph, "financial benefit" includes
honoraria, fees, stock, the value of the member's or immediate
family member's stock holdings, and any direct financial
benefit deriving from the finding of a review conducted under
this Act.
(2) A disclosure of interests under this Section shall
include the type, nature, and magnitude of the interests of
the member or the member's immediate family member involved.
(3) A conflict of interest shall be disclosed in advance
of the first open meeting after the conflict is identified or
within 5 days after the conflict is identified. A conflict of
interest shall be disclosed by:
(A) the Board when hiring Board staff;
(B) the appointing authority when appointing members
and alternate members to the Board and members to the
Council; and
(C) the Board when a member of the Board is recused in
any final decision resulting from a review of a
prescription drug product.

HB1443 Engrossed - 7 - LRB104 06394 BAB 16430 b
(4) A conflict of interest disclosed under this Section
shall be posted on the website of the Board unless the Chair of
the Board recuses the member from any final decision resulting
from a review of a prescription drug product.
(5) Members and alternate members of the Board, Board
staff, and third-party contractors may not accept any gift or
donation of services or property that indicates a potential
conflict of interest or has the appearance of biasing the work
of the Board.
Section 15. Powers and duties of the Board. In addition to
the powers set forth elsewhere in this Act, the Board may:
(1) adopt rules for the implementation of this Act;
and
(2) enter into a contract with a qualified,
independent third party for any service necessary to carry
out the powers and duties of the Board.
Unless permission is granted by the Board, a third party
hired by the Board may not release, publish, or otherwise use
any information to which the third party has access under its
contract.
Section 20. Prescription Drug Affordability Stakeholder
Council.
(a) The Prescription Drug Affordability Stakeholder
Council is created. The purpose of the Council is to provide

HB1443 Engrossed - 8 - LRB104 06394 BAB 16430 b
stakeholder input to assist the Board in making decisions as
required under this Act. The Council consists of 15 members
appointed within 90 days after the effective date of this Act
as follows:
(1) 3 members appointed by the Speaker of the House of
Representatives;
(2) 2 members appointed by the Minority Leader of the
House of Representatives;
(3) 3 members appointed by the President of the
Senate;
(4) 2 members appointed by the Minority Leader of the
Senate; and
(5) 5 members appointed by the Governor.
(b) The members of the Council shall have knowledge in one
or more of the following:
(1) the pharmaceutical business model;
(2) supply chain business models;
(3) the practice of medicine or clinical training;
(4) consumer or patient perspectives;
(5) clinical and health services research;
(6) the State's health care marketplace;
(7) the practice of community pharmacy; or
(8) the practice of pharmacy administration and
expertise in pharmacoeconomics.
(c) From among the membership of the Council, the Board
Chair shall appoint one member to be Council Chair.

HB1443 Engrossed - 9 - LRB104 06394 BAB 16430 b
(d) The term of a member is 3 years, except that the
initial members of the Council shall serve staggered terms as
required by the terms provided for members in Section 55.
(e) A member of the Council may not receive compensation
as a member of the Council, but is entitled to reimbursement
for travel expenses.
Section 21. Operationalization. Before the Board reviews
specific drugs for affordability and establishes any upper
payment limits, it must establish an operational plan for
distribution and access to a drug with an upper payment limit.
That operational plan shall address medication availability in
the State, pharmacy participation in rural and urban areas,
drug distribution in the State, patient access, access to
pharmacies in underserved areas, pharmacy deserts, and
keystone pharmacies that serve as primary access points for a
community.
Section 25. Drug cost affordability review.
(a) The Board shall limit its review of prescription drug
products to those that are:
(1) brand name drugs or biologics that, as adjusted
annually for inflation in accordance with the Consumer
Price Index, have:
(A) a wholesale acquisition cost of $60,000 or
more per year or course of treatment if less than a

HB1443 Engrossed - 10 - LRB104 06394 BAB 16430 b
year; or
(B) a wholesale acquisition cost increase of
$3,000 or more in any 12-month period;
(2) biosimilar drugs that have been on the market for
at least 3 years, that have a wholesale acquisition cost
that is not at least 20% lower than the referenced brand
biologic at the time the biosimilars are launched, and
that have been suggested for review by members of public,
medical professionals, and other stakeholders;
(3) generic drugs that, as adjusted annually for
inflation in accordance with the Consumer Price Index,
have a wholesale acquisition cost of at least $100 for a
30-day supply or course of treatment less than 30 days and
which increased by 200% or more during the immediately
preceding 12-month period, as determined by the difference
between the resulting wholesale acquisition cost and the
average of the wholesale acquisition cost reported over
the immediately preceding 12 months; and
(4) other prescription drug products that may create
affordability challenges for the State health care system
or patients, including, but not limited to, drugs to
address public health emergencies.
The Board shall prioritize establishing and implementing
upper payment limits for the 10 prescription drug products
with a Medicare Maximum Fair Price that went into effect in
2026 before proceeding with upper payment limits on other

HB1443 Engrossed - 11 - LRB104 06394 BAB 16430 b
prescription drug products with a Medicare Maximum Fair Price
or affordability reviews for any other prescription drug
products. Based on the implementation of the upper payment
limits, the Board shall make any necessary changes to the
operation plan. The Board may establish a maximum of 2 upper
payment limits on prescription drug products without a
Medicare Maximum Fair Price per calendar year.
The Board is not required to identify every prescription
drug that meets the criteria of this subsection.
(b) The Board shall solicit public input on prescription
drugs thought to be creating affordability challenges that
meet the parameters of paragraphs (1) through (4) of
subsection (a). The Board shall determine whether to conduct a
full affordability review for the proposed prescription drugs
after compiling preliminary information about the cost of the
product, patient cost sharing for the product, health plan
spending on the product, stakeholder input, and other
information decided by the Board.
(c) If the Board conducts a review of the cost and
affordability of a prescription drug product, the review shall
determine whether use of the prescription drug product that is
fully consistent with the labeling approved by the United
States Food and Drug Administration or standard medical
practice has led or will lead to affordability challenges for
the State health care system or high out-of-pocket costs for
patients.

HB1443 Engrossed - 12 - LRB104 06394 BAB 16430 b
(d) The information to conduct an affordability review may
include, but is not limited to:
(1) any document and research related to the
manufacturer's selection of the introductory price or
price increase of the prescription drug product;
(2) any patient assistance program or programs
specific to the product;
(3) any estimated or actual manufacturer product price
concessions in the market;
(4) any net product cost to State payers;
(5) the relevant factors contributing to the price
paid for the prescription drug, including the wholesale
acquisition cost, discounts, rebates, or other price
concessions;
(6) the average patient copayment or other cost
sharing for the drug;
(7) the effect of the price on consumers' access to
the drug in the State;
(8) whether the cost of the drug contributes to
inequities in the availability of health care to
underserved communities in the State;
(9) the price and availability of therapeutic
alternatives;
(10) input from any advisory groups established by the
Board;
(11) input from patients affected by the condition or

HB1443 Engrossed - 13 - LRB104 06394 BAB 16430 b
disease treated by the drug and individuals with medical
or scientific expertise related to the condition or
disease treated by the drug;
(12) life cycle management;
(13) the average cost of the drug in the State;
(14) market competition and context;
(15) projected manufacturer revenue, if available;
(16) off-label usage of the drug; and
(17) any other relevant factors and information as
determined by the Board.
(e) Failure of a manufacturer to provide the Board with
the information for an affordability review does not affect
the authority of the Board to conduct such a review.
(f) If the Board finds that the spending on a prescription
drug product reviewed under this Section has led or will lead
to an affordability challenge, the Board shall establish an
upper payment limit considering exceptional administrative
costs related to the distribution of the drug in the State.
(g) The upper payment limit applies to all purchases and
payor reimbursements, including reimbursements from health
benefit plans, of the prescription drug product intended for
use by individuals in the State, in person, by mail, or by
other means.
(h) Any information submitted to the Board in accordance
with this Section shall be subject to public inspection only
to the extent allowed under the Freedom of Information Act.

HB1443 Engrossed - 14 - LRB104 06394 BAB 16430 b
(i) This Section may not be construed to prevent a
manufacturer from marketing a prescription drug product
approved by the United States Food and Drug Administration
while the product is under review by the Board.
(j) Nothing in this Act requires a State department,
including, but not limited to, the Department of Healthcare
and Family Services, to disclose proprietary information or
information prohibited by federal law.
Section 30. Protections and other Board considerations.
(a) The Board shall examine how an upper payment limit
would affect a covered entity, as that term is defined in
Section 340B of the federal Public Health Service Act.
(b) In determining whether a drug creates an affordability
challenge or determining an upper payment limit amount, the
Board may not use cost-effectiveness analyses that include the
cost-per-quality adjusted life year or a similar measure to
identify subpopulations for which a treatment would be less
cost-effective due to severity of illness, age, or preexisting
disability. In addition, for any treatment that extends life,
if the Board uses cost-effectiveness results, the Board must
use results that weigh the value of all additional lifetime
gained equally for all patients, no matter their severity of
illness, age, or preexisting disability.
(c) An upper payment limit is effective no sooner than 6
months after it has been announced. The Board may suspend an

HB1443 Engrossed - 15 - LRB104 06394 BAB 16430 b
upper payment limit if it determines that there is a shortage
of the drug in the State, unless the Board determines that the
shortage was caused by a manufacturer or its agent.
(d) State-regulated health plans shall inform the Board of
how any upper payment limit-related cost savings are directed
to the benefit of enrollees, with a priority on enrollee cost
sharing.
(e) The upper payment limit shall not be inclusive of the
pharmacy dispensing fee, provider administration fee, or any
additional payment amount made by a payor to a provider for the
drug product related to the provider's procurement, handling,
storage, or other activity facilitating administration of the
drug product. The additional payment amount may be reflected
in the payor's fee schedule, provider contract, or any other
agreement governing reimbursement of the drug product and
associated services.
(f) If a prescription drug product subject to an upper
payment limit established under this Act is intended to be
made available for purchase by pharmacies, distributors, or
wholesalers licensed in this State, it shall be available at a
price that does not exceed the upper payment limit. If a
wholesaler or distributor acquires a prescription drug product
subject to an upper payment limit at a price that exceeds the
upper payment limit, the wholesaler or distributor is entitled
to a chargeback or rebate equal to the difference between the
price and the upper payment limit from the entity that sold the

HB1443 Engrossed - 16 - LRB104 06394 BAB 16430 b
product to the wholesaler or distributor.
(g) No pharmacy shall be required to dispense a
prescription drug product subject to an upper payment limit if
the product is not reasonably available for purchase at or
below the upper payment limit within a time frame consistent
with normal pharmacy ordering and delivery practices.
(g-1) Nothing in this Act shall require a pharmacy or
dispensing provider to dispense a prescription drug product at
a reimbursement rate below the pharmacy's actual acquisition
cost plus a reasonable professional dispensing fee.
(g-2) An upper payment limit established under this Act
shall apply only to the ingredient cost of a prescription drug
product and shall not limit, reduce, or otherwise affect the
professional dispensing fee paid to a pharmacy for the safe
and lawful dispensing of the medication.
(g-3) A pharmacy benefit manager shall not impose any fee,
clawback, reconciliation adjustment, performance adjustment,
or other financial assessment that has the effect of reducing
reimbursement to a pharmacy below the upper payment limit.
(g-4) Any fee or adjustment that results in reimbursement
below the upper payment limit shall constitute a violation of
this Act.
(g-5) For purposes of this subsection, "savings" means the
difference between the wholesale acquisition cost of a
prescription drug product before an upper payment limit and
the upper payment limit. All savings shall be applied in the

HB1443 Engrossed - 17 - LRB104 06394 BAB 16430 b
following order of priority: first, to reduce enrollee cost
sharing at the point of sale; second, to reduce premiums; and
third, to provide any other direct financial benefit to
enrollees.
(g-6) The pharmacy or pharmacist shall not be given the
administrative responsibility, either directly or indirectly,
of determining patient eligibility, enrollment into plans,
etc. Any administrative responsibility of enrolling patients
into a plan or providing coverage must be done through
enrollment in a State-managed health benefit plan.
(h) The Board shall not create an upper payment limit that
is different from the Medicare Maximum Fair Price for the
prescription drug product that has a Medicare Maximum Fair
Price.
(i) An upper payment limit shall be implemented no sooner
than the Medicare implementation date and shall not be subject
to the requirements of Section 25.
(j) Medicare Part C and D plans are not required to
reimburse at the upper payment limit.
(k) Any upper payment limit established by the Board shall
not apply to prescription drug products purchased by the
Department of Healthcare and Family Services for the medical
assistance program under Article V of the Illinois Public Aid
Code or to a health care plan serving Medicaid populations
that provides, arranges for, pays for, or reimburses the cost
of any health care service for persons who are enrolled under

HB1443 Engrossed - 18 - LRB104 06394 BAB 16430 b
the medical assistance program under Article V of the Illinois
Public Aid Code unless, after consultation with and approval
of the Director of Healthcare and Family Services, it is
determined that the upper payment limit would reduce costs to
the State.
(l) Any upper payment limit established by the Board shall
not apply to prescription drug products purchased or
reimbursed by the Department of Central Management Services in
conjunction with its administration of the State Employees
Group Insurance Program or any health care plan established or
maintained under the State Employee Group Insurance Act of
1971 unless, after consultation with and approval of the
Director of the Department of Central Management Services, it
is determined that the upper payment limit would reduce costs
to the State.
Section 35. Remedies. The Attorney General may enforce
this Act. The Attorney General may pursue any available remedy
under State law when enforcing this Act.
Section 40. Appeal of Board decisions.
(a) A person aggrieved by a decision of the Board may
request an appeal of the decision within 30 days after the
finding of the Board.
(b) The Board shall hear the appeal and make a final
decision within 60 days after the appeal is requested.

HB1443 Engrossed - 19 - LRB104 06394 BAB 16430 b
(c) Any person aggrieved by a final decision of the Board
may petition for judicial review in accordance with the
provisions of the Administrative Review Law.
Section 45. Prescription Drug Affordability Board Fund.
The Prescription Drug Affordability Board Fund is created as a
special fund in the State treasury. The Board shall be funded
by an annual assessment on all manufacturers whose products
are sold in the State. The total annual assessment shall be set
at the amount necessary to fund Board operations, not to
exceed $750,000 in any fiscal year, and shall be apportioned
equally among all manufacturers in the assessed class. A
manufacturer that does not sell drug products in the State
must submit a written statement to the Board certifying that
no drug product manufactured or distributed by that
manufacturer was sold in the State during the preceding fiscal
year to be exempt from the assessment. The Board shall collect
the annual assessment in accordance with rules adopted by the
Board. The rules shall specify the methodology and timeline
for collecting the assessment. All funds collected by the
Board from the assessments shall be deposited into the Fund.
The Fund shall be used only to provide funding for the Board
and for the purposes authorized under this Act, including any
costs expended by any State agency to implement this Act. All
interest earned on moneys in the Fund shall be credited to the
Fund. This Section may not be construed to prohibit the Fund

HB1443 Engrossed - 20 - LRB104 06394 BAB 16430 b
from receiving moneys from any other source that does not
create the appearance of a conflict of interest. The Board
shall be established using general funds, which shall be
repaid to the State with the assessments required under this
Section. The Board may not spend more than $750,000 annually
and funds that are not used in one fiscal year shall roll over
to the following fiscal year.
Section 50. Reports.
(a) On or before December 31 of each year, the Board shall
submit to the General Assembly a report that includes:
(1) price trends for prescription drug products;
(2) the number of prescription drug products that were
subject to Board review, including the results of the
review and the number and disposition of appeals and
judicial reviews of Board decisions; and
(3) any recommendations the Board may have on further
legislation needed to make prescription drug products more
affordable in this State.
(b) On or before June 1, 2027, the Board shall submit a
report to the General Assembly about the operation of the
generic drug market in the United States that includes a
review of physician-administered drugs and considers:
(1) the prices of generic drugs on a year-over-year
basis;
(2) the degree to which generic drug prices affect

HB1443 Engrossed - 21 - LRB104 06394 BAB 16430 b
insurance premiums as reported by health insurers in this
State or other states that collect this information;
(3) recent and current trends in patient cost sharing
for generic drugs;
(4) the causes and prevalence of generic drug
shortages; and
(5) any other relevant study questions.
(c) The Board shall notify the General Assembly if 5 years
have passed without any litigation hindering Board operations.
Section 55. Term expiration.
(a) The terms of the initial members and alternate members
of the Prescription Drug Affordability Board shall expire as
follows:
(1) one member and one alternate member in 2029;
(2) 2 members and one alternate member in 2030; and
(3) 2 members, including the Chair of the Board, and
one alternate member in 2031.
(b) The terms of the initial members of the Prescription
Drug Affordability Stakeholder Council shall expire as
follows:
(1) 5 members in 2029;
(2) 5 members in 2030; and
(3) 5 members in 2031.
Section 90. Repeal. This Act is repealed 5 years after the

HB1443 Engrossed - 22 - LRB104 06394 BAB 16430 b
effective date of this Act.
Section 97. Severability. If any provision of this Act or
the application thereof to any person or circumstance is held
invalid for any reason in a court of competent jurisdiction,
the invalidity does not affect other provisions or any other
application of this Act that can be given effect without the
invalid provision or application, and for this purpose the
provisions of this Act are declared severable.
Section 900. The State Finance Act is amended by adding
Section 5.1038 as follows:
(30 ILCS 105/5.1038 new)
Sec. 5.1038. The Prescription Drug Affordability Board
Fund. This Section is repealed 5 years after the effective
date of this amendatory Act of the 104th General Assembly.
Section 999. Effective date. This Act takes effect 180
days after becoming law.